HAC (Russian)
RSCI (Russian)
Ulrichsweb (Ulrich’s Periodicals Directory)
Scientific Indexing Services

Possibilities of using calcium lactate in combination with a prebiotic complex in the therapy of chronic dermatoses

DOI: https://doi.org/10.29296/25877305-2022-05-16

K. Katkova(1), T. Ramazanova(1), A. Belenkova(1), E. Denisova(1,2), Candidate of Medical Sciences; Professor I. Korsunskaya(2), MD; A. Kolodkin(3),
1-Center for Theoretical Problems of Physicochemical Pharmacology, Russian Academy of Sciences, Moscow
2-Moscow Research and Practical Center for Dermatovenereology and Cosmetology, Moscow Healthcare Department, Moscow
3-Scientific Society «Mikrobiota», Moscow Region, Sergiev Posad

There is now a lot of scientific evidence suggesting that the gut microbiome affects many human body organs, including the skin. In this connection, intensive study is being given to the possibility of including drugs that favors normalization of the composition of intestinal microflora in order to improve the skin process. These agents may include metabiotics and prebiotic complexes that contain substances that activate the growth of normal flora. There is evidence of a fairly common occurrence of dysbiosis and gastrointestinal disorders in atopic dermatitis (AD) and psoriasis. In this regard, the authors observed patients with AD and psoriasis who received combination therapy including calcium lactate and a prebiotic complex. The severity of symptoms was reduced just on days 3–5 days; whereas there was a significant clinical effect by day 14 of treatment. However, the mechanism of action of prebiotics on the course of psoriasis and AD requires further study.

gut microbiome
atopic dermatitis
calcium lactate

  1. He Y., Wu W., Zheng H.M. et al. Regional variation limits applications of healthy gut microbiome reference ranges and disease models. Nat Med. 2018; 24: 1532–5. DOI: 10.1038/s41591-018-0164-x
  2. Polkowska-Pruszynska B., Gerkowicz A., Krasowska D. The gut microbiome alterations in allergic and inflammatory skin diseases-an update. J Eur Acad Derm Venereol. 2020; 34: 455–64. DOI: 10.1111/jdv.15951
  3. Yoo J.Y., Groer M., Dutra S.V.O. et al. Gut Microbiota and Immune System Interactions. Microorganisms. 2020; 8: 1587. DOI: 10.3390/microorganisms8101587
  4. Ramirez-Bosca A., Navarro-Lopez V., Martinez-Andres A. et al. Identification of Bacterial DNA in the Peripheral Blood of Patients with Active Psoriasis. JAMA Dermatol. 2015; 151: 670–1. DOI: 10.1001/jamadermatol.2014.5585
  5. Ning L., Lifang P., Huixin H. Prediction Correction Topic Evolution Research for Metabolic Pathways of the Gut Microbiota. Front Mol Biosci. 2020; 7 :600720. DOI: 10.3389/fmolb.2020.600720
  6. Johnson C.C., Ownby D.R. The infant gut bacterial microbiota and risk of pediatric asthma and allergic diseases. Transl Res. 2017; 179: 60–70. DOI: 10.1016/j.trsl.2016.06.010
  7. Navarro-Lopez V., Ramirez-Bosca A., Ramon-Vidal D. et al. Effect of Oral Administration of a Mixture of Probiotic Strains on SCORAD Index and Use of Topical Steroids in Young Patients With Moderate Atopic Dermatitis: A Randomized Clinical Trial. JAMA Dermatol. 2018; 154: 37–43. DOI: 10.1001/jamadermatol.2017.3647
  8. Climent E., Martinez-Blanch J.F., Llobregat L. et al. Changes in Gut Microbiota Correlates with Response to Treatment with Probiotics in Patients with Atopic Dermatitis. A Post Hoc Analysis of a Clinical Trial. Microorganisms. 2021; 9: 854. DOI: 10.3390/microorganisms9040854
  9. Dzhordzhieva O.V., Togoeva L.Sh., Mel’nichenko O.O. et al. Izuchenie mikrobiotsenoza kozhi i kishechnika u bol’nykh atopicheskim dermatitom. Effektivnaya farmakoterapiya. 2012; 11: 32–5 (in Russ.).
  10. Dzhordzhieva O.V., Togoeva L.Sh., Dikovitskaya I.G. et al. Laktofil’trum v kompleksnoi terapii ekzemy. Effektivnaya farmakoterapiya. 2011; 11: 28–30 (in Russ.).
  11. Olejniczak-Staruch I., Ciążyńska M., Sobolewska-Sztychny D. et al. Alterations of the Skin and Gut Microbiome in Psoriasis and Psoriatic Arthritis. Int J Mol Sci. 2021; 22 (8): 3998. DOI: 10.3390/ijms22083998
  12. Fry L., Baker B.S., Powles A.V. Is chronic plaque psoriasis triggered by microbiota in the skin? Br J Dermatol. 2013; 169: 47–52. DOI: 10.1111/bjd.12322
  13. Fry L., Baker B.S., Powles A.V. et al. Psoriasis is not an autoimmune disease? Exp Dermatol. 2015; 24: 241–4. DOI: 10.1111/exd.12572
  14. Belkaid Y., Hand T.W. Role of the microbiota in immunity and inflammation. Cell. 2014; 157: 121–41. DOI: 10.1016/j.cell.2014.03.011
  15. Valdimarsson H., Baker B.S., Jonsdottir I. et al. Psoriasis: A T-cell-mediated autoimmune disease induced by streptococcal superantigens? Immunol Today. 1995; 16: 145–9. DOI: 10.1016/0167-5699(95)80132-4
  16. Leung D.Y., Travers J.B., Giorno R. et al. Evidence for a streptococcal superantigendriven process in acute guttate psoriasis. J Clin Invest. 1995; 96: 2106–12. DOI: 10.1172/JCI118263
  17. Scher J.U., Ubeda C., Artacho A. et al. Decreased bacterial diversity characterizes the altered gut microbiota in patients with psoriatic arthritis, resembling dysbiosis in inflammatory bowel disease. Arthritis Rheumatol. 2015; 67: 128–39. DOI: 10.1002/art.38892
  18. Alesa D.I., Alshamrani H.M., Alzahrani Y.A. et al. The role of gut microbiome in the pathogenesis of psoriasis and the therapeutic effects of probiotics. J Family Med Prim Care. 2019; 8: 3496–503. DOI: 10.4103/jfmpc.jfmpc_709_19
  19. Fry L., Baker B.S. Triggering psoriasis: The role of infections and medications. Clin Dermatol. 2007; 25: 606–15. DOI: 10.1016/j.clindermatol.2007.08.015
  20. Eppinga H., Sperna Weiland C.J. et al. Similar depletion of protective Faecalibacterium prausnitzii in psoriasis and inflammatory bowel disease, but not in hidradenitis suppurativa. J Crohns Colitis. 2016; 10: 1067–75. DOI: 10.1093/ecco-jcc/jjw070
  21. Fu Y., Lee C.H., Chi C.C. Association of psoriasis with inflammatory bowel disease: A systematic review and meta-analysis. JAMA Dermatol. 2018; 154: 1417–23. DOI: 10.1001/jamadermatol.2018.3631
  22. Ely P.H. Is psoriasis a bowel disease? Successful treatment with bile acids and bioflavonoids suggests it is. Clin Dermatol. 2018; 36: 376–89. DOI: 10.1016/j.clindermatol.2018.03.011
  23. Groeger D., O’Mahony L., Murphy E.F. et al. Bifidobacterium infantis 35624 modulates host inflammatory processes beyond the gut. Gut Microbes. 2013; 4: 325–39. DOI: 10.4161/gmic.25487
  24. Suarez-Farinas M., Li K., Fuentes-Duculan J. et al. Expanding the psoriasis disease profile: Interrogation of the skin and serum of patients with moderate-to-severe psoriasis. J Invest Dermatol. 2012; 132: 2552–64. DOI: 10.1038/jid.2012.184
  25. Vandeputte D., Falony G., Vieira-Silva S. et al. Prebiotic inulin-type fructans induce specific changes in the human gut microbiota. Gut. 2017; 66 (11): 1968–74. DOI:10.1136/gutjnl-2016-313271
  26. Morita N., Umemoto E., Fujita S. et al. GPR31-dependent dendrite protrusion of intestinal CX3CR1+ cells by bacterial metabolites. Nature. 2019; 566 (7742): 110–4. DOI: 10.1038/s41586-019-0884-1
  27. Chicherin I.Yu., Pogorelskiy I.P., Kolodkin A.M. et al. Role of colonization resistance of gastric and intestinal mucosa in the development of gastrointestinal bacterial infections. Infectious Diseases. 2019; 17 (3): 55–68 (in Russ.). DOI: 10.20953/1729-9225-2019-3-55-68
  28. Minushkin O.N., Maslovsky L.V., Ardatskaya M.D. et al. Clinical and metabolic effects of metaprebiotic therapy for some functional bowel diseases. Experimental and Clinical Gastroenterology. 2021; 10: 100–8 (in Russ.). DOI: 10.31146/1682-8658-ecg-194-10-100-108